BACKGROUND: The Children's Oncology Group AHOD0431 study evaluated a response-directed treatment paradigm in which minimal initial chemotherapy and low-dose radiation was received only by patients who did not achieve a complete remission, and a chemotherapy/low-dose radiation salvage regimen was received by those who had a protocol-defined, low-risk recurrence. METHODS: Patients younger than 21 years who had stage IA or IIA nonbulky disease were eligible. The treatment strategy was evaluated by determining the proportion that received minimal chemotherapy alone, the proportion that had a first or second remission without the receipt of high-dose chemotherapy/stem cell rescue or higher dose involved-field radiation therapy (>21 grays), and overall survival. RESULTS: In total, 278 patients were eligible. At 4 years, 49.0% had received minimal chemotherapy and no radiation, 88.8% were in remission without receiving high-dose chemotherapy with stem cell rescue or >21 grays of involved-field radiation therapy, and the overall survival rate was 99.6%. Patients who had mixed cellularity histology had a 4-year event-free survival (EFS) rate of 95.2%, which was significantly better than the 75.8% EFS for those who had nodular sclerosis histology (P 5.008). A red blood cell sedimentation rate 20 mm/hour and a negative fluorodeoxyglucose-positron emission tomography scan after 1 cycle of chemotherapy (PET1) were associated with a favorable EFS outcome. The study was closed early when the receipt of radiation therapy exceeded the predefined monitoring boundary. CONCLUSIONS: This limited chemotherapy response-based approach was successful in patients who had a negative PET1 result, had MC histology, or had a low red blood cell sedimentation rate. In this treatment paradigm, evaluation of increased chemotherapy intensity or the integration of active new agents is indicated for patients who have nodular sclerosis histology with a high ESR or who have a positive PET1 result. Cancer
INTRODUCTION
Treatment strategies for limited stage classical Hodgkin lymphoma (cHL) in children and adolescents vary. [1] [2] [3] A cure is reasonably expected in the great majority of children; however, the potential for long-term adverse sequelae of treatment remains significant. 4, 5 Event-free survival (EFS) may be improved by globally intensifying initial therapy, but an alternative approach is to accept lower EFS and rely on higher dose salvage for those who fail. The former approach risks toxicity for the larger cohort; however, the latter accepts lower EFS while minimizing toxic therapies, with overall survival (OS) maintained by salvage approaches that may include radiation or high-dose chemotherapy with stem cell rescue. Because EFS alone does not encompass the full value of initial therapy in cHL, our approach for limited stage cHL used a low-intensity initial chemotherapy regimen designed to limit cumulative exposure to chemotherapy agents associated with long-term toxicities.
Response-directed approaches tailor initial therapy for patients who demonstrate a favorable response to chemotherapy. [6] [7] [8] To our knowledge, no prior trial has paired limited, upfront chemotherapy with a salvage regimen for patients who develop recurrent disease to maintain OS while sparing upfront radiation therapy for those who have limited stage disease. The rationale for our approach was that many patients with limited stage cHL who relapse with low disease burden after chemotherapy alone can be successfully retreated with further chemotherapy and involved-field radiation therapy (IFRT) without the use of high-dose chemotherapy/stem cell rescue or higher dose radiation therapy. 9, 10 Our objective was to investigate a response-directed treatment paradigm that delivered minimal initial chemotherapy, with low-dose radiation reserved for those who did not achieve a complete response (CR), and integrating a conventional chemotherapy/low-dose radiation salvage regimen for protocol-defined, low-risk recurrence. We also evaluated the role of response measured by a fluorodeoxyglucosepositron emission tomography scan after 1 cycle of chemotherapy (PET1 response) as a marker of chemosensitivity. To more fully understand the true risk and benefit of our algorithm, the analysis included the outcome of initial therapy, the outcome of therapy for protocol-defined, low-risk relapse, and OS.
MATERIALS AND METHODS

Eligibility
Children, adolescents, and young adults, from ages 0 through 21 years, were eligible for study participation. Participants had newly diagnosed cHL and met the following criteria: Ann Arbor stage IA or IIA, nonbulky disease. Bulk disease was defined as either a mediastinal mass greater than one-third the greatest thoracic dimension on an upright posterior-anterior chest x-ray or a continuous aggregate of lymph node tissue that measured >6 cm in the longest transverse dimension in any lymph node area outside of the mediastinum.
Treatment Regimen and Response Criteria
Response determination was made by central imaging review after 1 and 3 cycles of chemotherapy. A negative FDG-PET result corresponded to an activity level at or below that of the mediastinal blood pool as determined by visual inspection, whereas a positive result was defined as greater than that of the mediastinal blood pool, because Deauville scoring was not customary at the time of the study. If FDG-PET data provided to central review were insufficient to provide a reading, then an analysis was performed according to the institutional reading when available. Equivocal cases, when neither central nor institutional positive or negative readings were available, were analyzed as positive. Gallium scan, with negative defined as no residual detection of increased isotope uptake compared with background, was substituted for an FDG-PET scan when the latter modality was not available. A CR was defined both as an anatomic reduction 80% in the product of the perpendicular dimension (PPD) and as an FDG-PET-negative result after 3 cycles of chemotherapy cycles (PET3). No residual lymph node mass could measure >2.0 cm in maximal transverse dimension, with the exception of the mediastinal mass, which could measure >2 cm provided that it demonstrated a reduction 80% in the PPD. A partial response (PR) was defined by a reduction 50% in the PPD of each of the areas of measurable disease or a return to normal lymph node size that did not constitute a CR, regardless of FDG-PET response. Progressive disease (PD) was defined as an increase 50% in the PPD of any of the involved lymph nodes, or nodal masses, or new lesion(s)' or progression of a nonmeasurable, assessable disease site. Stable disease (SD) was defined as less than a PR but not PD. A low-risk relapse was defined as any recurrence that was stage IA or IIA nonbulky disease occurring after achieving a CR with chemotherapy alone, regardless of the time to relapse. Any other relapse was defined as a high-risk relapse.
The initial treatment regimen consisted of doxorubicin 25 mg/m 2 on days 1 and 2, vincristine 1.4 mg/m 2 (maximum, 2.8 mg) on days 1 and 8, prednisone 20 mg/ m 2 twice daily on days 1 through 7, and cyclophosphamide 600 mg/m 2 on days 1 and 2 given every 21 days with growth factor support for 3 cycles (AVPC). Patients who were not in complete remission after 3 cycles received 21 grays (Gy) of IFRT in 1.5-Gy fractions over 14 sessions. Participants who experienced a protocol-defined, low-risk relapse after initial chemotherapy alone were eligible for an integrated salvage regimen consisting of vinorelbine 25 mg/ m 2 per dose on days 1 and 5 and ifosfamide 3000 mg/m 2 daily as a continuous 24-hour infusion on days 1 through 4 given every 21 days with growth factor support for 2 cycles (VI); followed by dexamethasone 5 mg/m 2 every 12 hours on days 1 and 2, etoposide 100 mg/m 2 every 12 hours on days 1 and 2, cisplatin 90 mg/m 2 on day 1, and cytarabine 3000 mg/m 2 every 12 hours on days 1 and 2 given every 21 days with growth factor support for 2 cycles (DECA). Patients on a salvage regimen then received IFRT. IFRT was received at a dose of 21 Gy in 1.5-Gy fractions over 14 sessions to areas defined as involved at initial presentation and to other areas involved at recurrence.
Statistical Considerations
EFS was defined as the time from study entry to the first occurrence of disease relapse/progression, second malignancy, or death from any cause; patients without reports of such events were censored at the last contact. OS was defined as the time from study entry to death from any cause; and patients who remained alive at last contact were censored.
Alternate endpoints of EFS without radiation therapy (EFS no RT) and intensive therapy-free survival (ITFS) were evaluated in this trial of limited stage cHL. EFS no RT was defined from the time of study entry to the time of IFRT, as prescribed by study protocol or at treatment failure. An event for the endpoint of EFS no RT was defined as follows: less than a CR after initial chemotherapy, any relapse from a CR after initial chemotherapy, any second malignancy, or death from any cause. ITFS was defined as the time from study entry to an indication for high-dose chemotherapy/stem cell rescue (hematopoietic stem cell transplantation [HSCT]) or > 21 Gy IFRT. Events for ITFS were as follows: protocol-defined, high-risk relapse, Figure 1 . Flow diagram of the study. AVPC, indicates combined doxorubicin, vincristine, prednisone, and cyclophosphamide; CR, complete response; VI/DECA, vinorelbine and ifosfamide followed by combined dexamethasone, etoposide, cisplatin, and cytarabine with growth factor support; IFRT, involved-field radiation therapy; PET1, status of a fluorodeoxyglucose-positron emission tomography scan after 1 cycle of chemotherapy; PR, partial response; SD, stable disease; SMN, second malignant neoplasm.
any relapse after protocol-directed IFRT (upfront or protocol-prescribed salvage for protocol-defined, low-risk relapse in CR), any second malignancy, or death from any cause. Protocol-defined, low-risk relapses after CR were not considered failures for ITFS. On the basis of an intention-to-treat principle, all patients who had a protocol-defined, low-risk relapse after a CR were analyzed as though they had received protocol salvage; their second relapses were included in ITFS.
The treatment strategy was intended to maintain an acceptable EFS rate while minimizing exposure to other than minimal chemotherapy (defined as EFS no RT) and minimizing the need for intensive retrieval. Study targets included: 1) a 4-year EFS no RT rate 65%, a 2) a 4-year ITFS rate 95% (which limits exposure to intense therapies like HSCT to <5% of the treatment population), and 3) a 4-year EFS 80%. The planned study sample size was 400 patients, with a minimum of 2 years of follow-up on the last enrolled patient. The power was > 95% to detect a reduction in the 4-year EFS rate from the null hypothesis of 0.80 to a rate of 0.74, a reduction in 4-year EFS no RT rate from the null hypothesis of 0.65 to a rate of 0.58, and a reduction in the 4-year ITFS rate from the null hypothesis of 0.95 to a rate of 0.91, based on a 1-sided test of the 4-year productlimit estimate with a 20% Type I error and as much as 20% censoring over the length of the study. The Kaplan-Meier product-limit method was used to estimate these endpoints and OS, along with the Greenwood standard error estimates and 95% confidence intervals (CIs) based on the log-log transformation. Although survival curves were directly compared between groups with k-sample tests, multivariate Cox regressions were performed to verify the difference between the groups by including the possible covariates.
CR and EFS rates according to ESR and C-reactive protein (CRP) were conducted using the Pearson chisquare test and the log-rank test, respectively. All analyses were conducted using the STATA statistical software package (StataCorp LP, College Station, TX).
RESULTS
The study opened to enrollment starting February 13, 2006 , and enrolled 287 patients, of whom 9 were subsequently identified as ineligible; therefore, 278 patients are the subject of this report (Fig. 1) . Twenty-two patients had Gallium scans as their sole nuclear medicine imaging modality to document response at the end of 3 cycles of chemotherapy. In 7 patients, the PET3 materials provided to central review were insufficient for response determination. Three of these cases were equivocal and were analyzed as positive. On December 4, 2008, the study was temporarily closed to accrual because of a high risk of relapse among patients with a CR who had a positive PET1 result. A study recommendation was made for all patients who had a positive or unknown PET1 result to receive 21-Gy IFRT unless it was >12 months after they had completed chemotherapy. The study was closed on April 3, 2009, when the EFS no RT rate dropped below the predefined goal. The median follow-up was 77 months from enrollment. Patient characteristics are presented in Table 1 .
Toxicity
Treatment-related toxicity was minimal during initial therapy. The most common toxicity was febrile neutropenia, which occurred in 5.4% of patients. Nonhematologic Common Toxicity Criteria for Adverse Events (version 4.0) grade 3 toxicities occurred in < 5% of patients.
Toxicity during the VI salvage regimen (n 5 23) included a 17.4% incidence of febrile neutropenia, 13% incidence of grade 3 vomiting, 13% incidence of infections, and 8.7% incidences of grade 3 nausea and hypophosphatemia. The DECA portion of the salvage regimen (n 5 21) was associated with a 9.5% incidence of febrile neutropenia and 9.5% incidences of grade 3 hearing impairment, tinnitus, infections, vomiting, and hypokalemia.
Outcomes
After 3 cycles of AVPC chemotherapy CR was achieved in 175 patients (64%) achieved a CR, 95 (34%) achieved a PR, and 5 (2%) had SD. Among those who attained a CR, 13 patients had completed chemotherapy The 4-year EFS rate for the whole cohort was 79.9 % (95% CI, 74.6%-84.2%) (Fig. 2A) . First events included 52 relapses and 3 second malignant neoplasms (SMNs). The 4-year EFS rate was 77.5% (95% CI, 70.8%-83.4%) for patients who had a CR and 82.8% (95% CI, 73.4%-89.1%) (P 5 .27) for those who had a PR or SD (Fig. 2B) .
At 4 years, the EFS no RT was 49.0% (95% CI, 42.8%-54.9%) (Supporting Fig. 1A ). In total, 137 events were reported for the EFS no RT endpoint. Failures were caused by lack of a CR at the end of initial chemotherapy (n 5 100), relapse after an initial CR (n 5 37), or an SMN (n 5 1).
The 4-year OS rate was 99.6% (95% CI, 97.0%-99.9%) (Fig. 2A) . One death from progressive disease occurred in a patient who had a PR after chemotherapy, then received radiation therapy according to the protocol, but relapsed with stage IV disease 7.5 months after enrollment.
Protocol-Directed Salvage Therapy Outcomes and ITFS
The median time to first relapse among patients who had a CR was 9.4 months (range, 4.1-49.7 months). Among 31 patients who were eligible for the study salvage regimen, 11 did not receive protocol-prescribed salvage. Stated reasons for not following protocol were: the study was open only to follow-up with the local institutional review board, treating physician preference, and patient/ family preference. An institutional query revealed that none of these patients received high-dose chemotherapy with stem cell rescue as salvage for first relapse. The 4-year ITFS was 88.8% (95% CI, 84.3%-92.1%) (Supporting Fig. 1B) . Combining the patients with CR and PR/SD, in total, 29 events occurred for ITFS. Failures for ITFS among patients who had a CR included: protocoldefined, high-risk relapses (n 5 5), second relapses (n 5 7), and an SMN (n 5 1). Among the 100 patients who had PR/ patients, 16 failures for ITFS occurred (recurrences, n 5 14; SMNs, n 5 2).
Risk Factor Analysis at Initial Diagnosis
Predictors of CR and EFS among all patients and among those with NS histology are presented in Table 2 . ESR and CRP were not prognostic for MC histology. In multivariable analysis, MC histology (hazard ratio [HR], 0.21; P 5 .04) and ESR 20 mm/hour (HR, 0.41; P 5 .03) Cancer remained significant predictors of EFS among all patients (Supporting Table 1 ).
Outcomes by Centrally Reviewed Histology
In total, 221 participants had centrally reviewed histology available. Those who did not have centrally reviewed histology available did not differ from the rest of the study population by sex, ethnicity, disease stage, ESR, CRP, or the number of disease sites. Patients without central histology review had a lower percentage of whites and a higher percentage of patients of unknown race (P 5 .04) (Supporting Table 2 ). MC histology was present in 19% of enrolled patients (n 5 42) for whom centrally reviewed pathology was available. Compared with patients who had NS histology, those who had with MC histology were more likely to be male (P < .0001), to be of Hispanic ethnicity (P 5 .02), to have stage I disease (P < .0001), to have lower end CRP levels (P 5 .03), and to have <3 disease sites (P 5 .02) (Supporting Table 3 ). The 4-year EFS rate among patients who had MC histology was 95.2% (95% CI, 82.3%-98.8%), which was significantly better than the 4-year EFS rate of 75.8% (95% CI, 68.5%-81.6%) among those who had NS histology (P 5 .008) (Fig. 3A) . This superiority remained significant in a multivariable Cox regression model (HR, 0.21; P 5 .038) (Supporting Table 1 ). However, there was no difference in CR rates after initial chemotherapy according to histology (MC vs NS, 69.1% vs 61.4%; P 5 .35). The 2 relapses among the 42 patients who had MC histology included 1 relapse in a patient who achieved a CR with initial chemotherapy and another in a patient with a PR who received IFRT.
PET1 Results
PET1 results were evaluable for 227 patients. There was no difference in demographics, histology, disease stage, CRP, or number of disease sites between those who did and did not have PET1 results available. However those without a PET1 result were more likely to have an ESR >20 mm/hour (P 5 .05) (Supporting Table 4 ). Among 227 patients who had PET1 scans, 49% had negative PET1 results. In 8 scans, the PET1 materials provided to central review were insufficient for response determination. In 1 of these scans, the results were equivocal, and it was analyzed as positive; the remaining scans were analyzed according to the institutional report. Patients who had positive PET1 results did not differ from those who had negative PET1 results by demographics, disease histology, or the number of disease sites. However, PET1-positive patients were more likely have stage II disease (P 5 .0034), an ESR > 20 mm/hour (P < .0001), and an elevated CRP level at presentation (P 5 .044) (Supporting Table 5 ). The 4-year EFS rate was significantly higher at 88.2% (95% CI, 80.5%-93.0%) for PET1-negative patients compared with 68.5% (95% CI, 58.7%-76.4%) for PET1-positive/equivocal patients (P 5 .0007) (Fig.  3B) . Compared with PET1-positive/equivocal patients, the PET1-negative population still had significantly better performance in terms of EFS after demographics and baseline characteristics were considered in a multivariable Cox regression model (HR, 0.39; P 5 .012) (Supporting Table 6 ). Among patients who achieved a CR after 3 cycles of chemotherapy and did not receive IFRT, the 4-year EFS rate was 84.9% (95% CI, 74.9%-91.1%) for PET1-negative patients (n 5 81) versus 59.6% (95% CI, 44.1%-72.0%) for PET1-positive/equivocal patients (n 5 48) (P 5 .001). Among patients who had a PR after 3 cycles of chemotherapy and received IFRT, the 4-year EFS rates for PET1-negative patients (n 5 25) versus PET1-positive/equivocal patients (n 5 51) were 96.0% (95% CI, 74.8%-99.4%) versus 69.5% (95% CI, 53.8%-80.7%), respectively (P 5 .015).
Second Malignant Neoplasms
There have been 3 SMNs. Two secondary cases of acute myeloid leukemia occurred, including one 4 years after completing chemotherapy only in a patient who had a CR and another 2.8 years after the completion of IFRT in a patient who had a PR. Thyroid carcinoma occurred in 1 patient who had cervical lymph node Hodgkin lymphoma 2 years after completing IFRT based on PR status. There have been no SMNs in patients who received the salvage regimen and no deaths from SMN.
DISCUSSION
We evaluated anatomic and FDG-PET response after 3 cycles of AVPC chemotherapy as a marker of sufficiency of treatment as well as the role of a very early FDG-PET response as an indicator of chemosensitivity. The paradigm allowed us to successfully treat almost one-half of our patients with only 3 cycles of AVPC chemotherapy, achieving an OS rate of 99.6%. Patients with MC histology also had high EFS and OS with this approach. Incorporating a uniform salvage regimen for protocol-defined, low-risk recurrences after chemotherapy only, in an effort to minimize the use of high-dose chemotherapy with stem cell rescue or >21-Gy IFRT, yielded an ITFS rate of 88.8%. In addition, we demonstrated that, despite a lower EFS than contemporary trials for limited stage cHL, a substantial majority of patients could avoid high-dose
Cancer chemotherapy with stem cell rescue procedures.
2,3
Extended follow-up will be required to fully assess the value of this strategy with regard to late effects, including the consequences of 21-Gy IFRT in almost one-half of patients.
Our current study was limited to participants who had stage I/IIA, nonbulky disease, but it did include patients who had high ESR, high CRP, and multiple sites of disease, factors that have previously been associated with a less favorable outcome.
11 Unfavorable prognostic indicators are expected to correlate with outcome in the setting of a reduced-intensity regimen. 12 Despite the inclusion of patients with unfavorable risk criteria, the 4-year OS rate was excellent; and the ITFS, although it was below the protocol target, was 88.8%. Our data suggest that patients who have limited stage, nonbulky disease with NS histology and an ESR 20 mm/hour, those who have a negative PET1 result, and patients who have MC histology could receive successful treatment with a minimal initial chemotherapy approach, supporting a riskbased and response-based approach in this group.
Although our EFS differed from that reported in earlier studies, the proportion of patients who received successful treatment without radiation therapy was higher than that reported in most contemporary limited-stage pediatric trials when the analysis is limited to cHL. 2, 3 We identified high ESR, NS histology, and a positive PET1 result as poor prognostic features in the setting of this minimal chemotherapy approach, and these potentially justify augmentation of therapy. Although IFRT in these patients may improve the overall EFS rate, some patients in this cohort may be treatable without IFRT if the intensity or duration of chemotherapy is increased after the PET1 response. This also may be a population for consideration of novel targeted agents or immune-modulating therapy. Our results concur with a preliminary report on the EuroNet-PHL-C1 study suggesting that high ESR as well as bulky disease are adverse prognostic indicators within their TG1 cohort (stage IA/IB-IIA). 13 Further evaluation of regimens with limited long-term toxicities or the integration of novel or targeted agents to minimize the need for radiation therapy in patients with these prognostic factors who have NS histology should be considered.
Therapy for recurrent Hodgkin lymphoma often involves high-dose chemotherapy with autologous stem cell rescue, sometimes in association with additional radiation therapy to selected regions. 9, 10 A unique aspect of the current study was the inclusion of a standardized salvage regimen for protocol-defined, low-risk recurrences after chemotherapy alone. We considered that this retrieval regimen of VI/DECA with 21-Gy low-dose IFRT was a preferable alternative to autologous HSCT. However, cumulative doses of chemotherapy have potential to confer long-term risks, particularly those related to fertility in males and females.
14 In all, 88.2% of patients received effective treatment without high5dose chemotherapy or > 21-Gy IFRT, demonstrating the utility of a combined-modality salvage regimen for recurrent disease after limited initial chemotherapy. Although 5 patients who recurred after initial chemotherapy alone had protocol-defined, high-risk relapses, the current OS rate for these patients is 100%.
In the current trial, the PET1 result was a significant predictor of EFS after AVPC chemotherapy alone when we used a conservative definition of favorable response of metabolic activity less than or equal to that of the mediastinal blood pool (now equated to a Deauville score of 2). It has been demonstrated previously in various studies (primarily among adults) that an early FDG-PET response is prognostic, typically after 2 or 3 cycles of chemotherapy and in a variety of risk strata. 15, 16 However, very early PET scanning after 1 cycle in children and adolescents who have limited stage disease has not previously been reported. The implications for dose modification based on this observation remain to be explored, with the potential for minimization of therapy for favorable very early responders or augmentation of therapy for those without an early metabolic response. 7 The potential to identify candidates for therapy augmentation after the first cycle of chemotherapy may allow for maximal therapeutic intervention without substantially prolonging therapy duration or adding to cumulative doses of cardiotoxic or gonadotoxic agents.
Notably, in contrast to prior North American or European cohorts, our current cohort had a high rate of MC histology and demonstrated excellent EFS after 3 cycles of AVPC and response-based IFRT in patients who had MC histology. MC disease is more common in younger children and children of Hispanic ethnicity. This difference in response of MC disease compared with NS disease has not been previously reported in limited stage, pediatric cHL. Although lymphocyte-predominant disease is now treated as a separate entity, recent trials in pediatric cHL have not stratified patients who have MC histology differently according to risk or treatment pathways. This new observation should prompt further investigation regarding the biologic differences of limited stage Hodgkin lymphoma with MC histology, its association with EpsteinBarr virus disease, and MC-specific treatment regimens.
In conclusion, results from the AHOD0431 study suggest a potential strategy for limiting chemotherapy in patients who have limited stage Hodgkin lymphoma with NS histology plus a low ESR and in those who have MC histology using very early PET1 response-based modification of therapy and an integrated, conventional chemoradiotherapy salvage regimen for protocol-defined, low-risk relapse. The prognostic factors identified herein may lead to better tailoring of therapy beyond stage. We demonstrate the principle and utility of paired salvage regimens after upfront low-dose chemotherapy, which allowed us to spare of the majority of patients potentially unnecessary treatment intensity. Our novel endpoints, EFS no RT and ITFS, comprise a paradigm with which to facilitate the analysis of trials focused on reduction of therapy in which EFS alone is inadequate. Future directions include exploration for augmentation of therapy for patients who have a high ESR or an unfavorable response to the first cycle of chemotherapy, incorporation of MC histology into treatment stratification for limited stage Hodgkin lymphoma, and optimization of salvage regimens for recurrences after minimal initial therapy in patients who have limited stage Hodgkin lymphoma.
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